Engineered Nanovaccine Targeting Clec9a+ Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist-Reference-Cited by-同舟云学术

Engineered Nanovaccine Targeting Clec9a+ Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist

Author:

Gou Shanshan¹,Liu Wenwen¹,Wang Shuai¹,Chen Guanyu²,Chen Zhenzhen¹³⁴^ORCID,Qiu Lu¹³⁴,Zhou Xiuman²,Wu Yahong¹³⁴,Qi Yuanming¹³⁴,Gao Yanfeng²^ORCID

Affiliation:

1. School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China

2. School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China

3. Henan Key Laboratory of Bioactive Macromolecules, Zhengzhou University, Zhengzhou 450001, China

4. International Joint Laboratory for Protein and Peptide Drugs of Henan Province, Zhengzhou University, Zhengzhou 450001, China

Funder

National Natural Science Foundation of China

Guangdong Province

Shenzhen Science and Technology Program

Publisher

American Chemical Society (ACS)

Subject

Mechanical Engineering,Condensed Matter Physics,General Materials Science,General Chemistry,Bioengineering

Link

Reference56 articles.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献